ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the UBS Global Life Sciences conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Wednesday, September 19, 2012 at 9:00 a.m. (ET).
The ARIAD presentation at the UBS Global Life Sciences Conference will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will also be available and archived on the site for three weeks.
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).